SCYNEXIS (SCYX) Stock Forecast: StockMap's 2-Week Call
SCYX stock forecast: StockMap's model makes no two-week call on SCYNEXIS after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 4 of 6 two-week windows on SCYX since Aug 21; by chance, a call on the same dates was right 60% of the time.
SCYNEXIS last closed at $2.60, -7.80% on the session.
Against the IVW growth benchmark the position is -5.47% over the forecast window.
SCYNEXIS' market cap is $25.88M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where SCYX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
33 daily calls for SCYX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks SCYNEXIS in the 27th percentile on return on equity, where 100 is best.
SCYNEXIS is classified under Health Care / Pharmaceuticals.
StockMap tracks SCYNEXIS as the 120th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite SCYNEXIS ranks 44th of 153 in the group, against a group median of -0.36.